Please login to the form below

Not currently logged in
Email:
Password:

macular oedema

This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Bayer drop AMD combination

Regeneron and Bayer drop AMD combination

Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival Novartis. ... advance the duo into phase III in either AMD or diabetic macular oedema.

Latest news

  • Lucentis claims speedy FDA review for myopia complication Lucentis claims speedy FDA review for myopia complication

    in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.

  • NICE backs Bayer’s Eylea as first-line BRVO treatment NICE backs Bayer’s Eylea as first-line BRVO treatment

    This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin

  • NICE gives Bayer's Elyea a provisional 'no' for first-line use NICE gives Bayer's Elyea a provisional 'no' for first-line use

    The provisional guidance in NICE's Appraisal Consultation Document only recommends Eylea in visual impairment in adults caused by macular oedema if laser photocoagulation has not been beneficial or is not ... NICE has previously recommended Eylea to

  • NICE backs Bayer's Eylea in diabetic eye condition NICE backs Bayer's Eylea in diabetic eye condition

    Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema (DMO). ... It also represents Eylea's third NICE recommendation, following positive guidance for wet age-related macular

  • NICE no for new eye disease drug NICE no for new eye disease drug

    There are few treatments for this disease outside of steroids. This is contrast to a similar condition known as wet eye age-related macular oedema, which has a number of blockbuster

More from news
Approximately 8 fully matching, plus 42 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics